Patents Assigned to Merck
  • Organic electroluminescent device
    Patent number: 11611046
    Abstract: The present invention relates to organic electroluminescent devices, the emitting layer thereof containing a blend of a luminescent material having a narrow singlet-triplet gap and a fluorescent emission material having high steric shielding.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: March 21, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Christof Pflumm, Anja Jatsch, Joachim Kaiser
  • Ethynyl derived composite, a composition comprising thereof, a method for manufacturing a coating by it, and a method for manufacturing a device comprising the coating
    Patent number: 11609498
    Abstract: [Problem to be Solved] An object is to provide a compound with good heat resistance. And another object is to provide a coating made exhibits less film shrinkage, good gap filling property and good planarization. [Solution] The present invention provides an ethynyl derived composite and a composition comprising thereof. And the present invention provides a method for manufacturing a coating by it, and a method for manufacturing a device.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: March 21, 2023
    Assignee: MERCK PATENT GMBH
    Inventors: Shigemasa Nakasugi, Yusuke Hama, Hiroshi Yanagita, Takashi Sekito, Yuriko Matsuura
  • MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT
    Publication number: 20230083431
    Abstract: The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: December 15, 2020
    Publication date: March 16, 2023
    Applicants: Merck Sharp & Dohme LLC, MSD International GMBH (Singapore Branch), Agency for Science, Technology and Research
    Inventors: Nicolas C. Boyer, Michael B. Garrigou, Sookhee Nicole Ha, Chunhui Huang, Anthony W. Partridge, Tomi K. Sawyer, Pietro Aronica, Charles W. Johannes, Srinivasaraghavan Kannan, Chandra S. Verma, Tsz Ying Yuen
  • COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20230084690
    Abstract: The present invention relates to novel ophthalmic devices comprising polymerized compounds comprising a photoactive unit, said polymerized compounds, and special monomer compounds being particularly suitable for compositions and ophthalmic devices.
    Type: Application
    Filed: April 17, 2020
    Publication date: March 16, 2023
    Applicant: MERCK PATENT GMBH
    Inventor: Stefan GERSTENECKER
  • AMIDO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES
    Publication number: 20230077499
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Andrew John Cooke, Robert Patrick Hayes, Marc A. Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Jeffrey W. Schubert, David M. Tellers
  • METHODS FOR PRODUCING STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE CARRIER PROTEIN CONJUGATES
    Publication number: 20230077640
    Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 16, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Patrick Leonard Ahl, Akhilesh Bhambhani, Christopher Jon Farrell, Patrick McHugh, Morrisa C. Jones, Daniel D. Roth, Jessica R. Sinacola, Justin Stanbro, Matthew P. Watson, Emily Wen, Michael A. Winters
  • Formulation of an organic functional material
    Patent number: 11603479
    Abstract: The present invention relates to a formulation containing at least one organic functional material and at least three different organic solvents, selected from at least two different organic solvents A and at least one organic solvent B, wherein at least one organic solvent A has a boiling point in the range from 250 to 350° C. and a viscosity of ?15 mPas, the at least one organic solvent B has a boiling point in the range from 200 to 350° C. and a viscosity of ?10 mPas, and the solubility of the at least one organic functional material in the second organic solvent B is ?5 g/l; as well as to electroluminescent devices prepared by using these formulations.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: March 14, 2023
    Assignee: MERCK KGAA
    Inventors: Gaëlle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Manuel Hamburger, Margarita Wucherer-Plietker
  • Frame for holding filtration assemblies and testing unit for microbiological testing
    Patent number: 11602754
    Abstract: The invention concerns a frame (1) for holding a plurality of filtration assemblies (100) and a testing unit (10) for microbiological testing. The frame (1) for holding the plurality of filtration assemblies (100) comprises an array of supports (5) each configured to receive and support one of the filtration assemblies (100) on a common support plane (2), and connection means (6) provided on the periphery (7) of the frame (1) and configured to releasably connect, by a form-locking engagement, a further frame (1) such that the common support planes (2) of the connected frames (1) are contiguous. Further, the testing unit (10) comprises at least one frame (1) packed in a bag (20) in pre-sterilized condition.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: March 14, 2023
    Assignee: Merck Patent GmbH
    Inventors: Philippe Rivat, Mathieu Arrault
  • Aggrecan binding immunoglobulins
    Patent number: 11603401
    Abstract: The present invention relates to immunoglobulins that specifically bind Aggrecan and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit the activity of Aggrecan.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: March 14, 2023
    Assignees: Ablynx N.V., Merck Patent GmbH
    Inventors: Soren Steffensen, Gerald Beste, Guy Hermans, Hans Gühring, Christoph Ladel, Lars Toleikis
  • METHODS OF SEPARATING HOST CELL LIPASES FROM AN ANTI-LAG3 ANTIBODY PRODUCTION
    Publication number: 20230077205
    Abstract: Provided herein are methods of separating host cell lipases from an anti-LAG3 antibody or antigen binding fragment in chromatographic processes and methods of improving polysorbate-80 stability in an anti-LAG3 antibody formulation by separating host cell lipases from the anti-LAG3 antibody or antigen binding fragment using chromatographic processes. Also provided are pharmaceutical compositions comprising an anti-LAG3 antibody or antigen binding fragment and less than 2 ppm of a host cell lipase.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Colette M. CUTLER, Hong LI, Sketa PATEL, Sandra E. RIOS, John P. WELSH
  • PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES
    Publication number: 20230075760
    Abstract: The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Julie Marie Skinner
  • METHODS FOR MONITORING THE PROGRESS OF POLYSACCHARIDE SIZE-REDUCTION
    Publication number: 20230073288
    Abstract: The present invention relates to Polysaccharide Size-Reduction Monitoring Methods useful for the non-invasive, and accurate monitoring of the progress of a polysaccharide size-reduction process.
    Type: Application
    Filed: February 24, 2021
    Publication date: March 9, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jennifer C. P. Wang, Kelsey A. Richards, Jayesh Desai, Bhumit A. Patel, Michael A. Winters, Patrick M. McHugh, Philip R. Kuhl, John P. Higgins, Michael I. Larkin, Michelle H. Chen
  • FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS
    Publication number: 20230061673
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: July 26, 2022
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • REUSE OF INTEIN-BOUND RESINS FOR PROTEIN PURIFICATION
    Publication number: 20230064395
    Abstract: The present disclosure relates to methods of protein purification by attaching an intein-C fragment to a target protein, passing a sample containing the intein-C tagged protein over a chromatographic resin carrying an intein-N fragment so as to create an intein-N intein-C complex, releasing the target protein from the intein-C fragment, and regenerating the column under conditions that disrupt the intein-N intein-C complex while preserving column functionality for multiple reuses.
    Type: Application
    Filed: March 23, 2021
    Publication date: March 2, 2023
    Applicant: Merck Patent GmbH
    Inventors: Oliver RAMMO, Romas SKUDAS
  • USE OF BIOMARKERS IN IDENTIFYING PATIENTS THAT WILL BE RESPONSIVE TO TREATMENT WITH A PRMT5 INHIBITOR
    Publication number: 20230062119
    Abstract: The present invention includes methods of identifying a patient who will likely be responsive to treatment with a protein arginine N-methyltransferase 5 inhibitor, or a pharmaceutically acceptable salt thereof, and methods of treating the same.
    Type: Application
    Filed: December 16, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Benjamin Nicholson, Rachel Allison Altura, Razvan Cristescu, David John Curtis, Ian Philip Street
  • STAPLED TRIAZOLE CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    Publication number: 20230063794
    Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
  • LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS
    Publication number: 20230061307
    Abstract: The invention relates to a liquid-crystalline medium having a nematic phase comprising one or more compounds of formula X wherein the parameters have the meaning given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type and to the use of the compounds of formula X for improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds, as well as to certain compounds of formula X, as specified in the text.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 2, 2023
    Applicant: MERCK PATENT GMBH
    Inventors: Atsutaka MANABE, Constanze BROCKE, Susan (Min Tzu) CHUANG, Sven Christian LAUT, Sabrina PFEIFFER, Ramin TAVAKOLI
  • INDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES
    Publication number: 20230066268
    Abstract: The present invention relates to novel Indazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5 and R6 are as defined herein. The present invention also relates to compositions comprising at least one Indazole Derivative, and methods of using the Indazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 15, 2020
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew John Cooke, Christopher D. Cox, Scott D. Edmondson, Charles Lee Jayne, Anilkumar G. Nair, Jeffrey W. Schubert, Jason W. Skudlarek, David M. Tellers, De-Yi Yang
  • Label
    Patent number: D980323
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: March 7, 2023
    Assignee: Merck KGaA
    Inventors: Sven Erfurth, Christian Kuechenthal, Jeffrey Whitford
  • Water purifier
    Patent number: D981529
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: March 21, 2023
    Assignee: Merck Patent GmbH
    Inventors: Camillo König, Dény Saraliev, Fabien Jeannerot, Gérald Lelong